Monday, Takeda Pharmaceutical Company Limited (NYSE:TAK) and AC Immune SA (NASDAQ:ACIU) announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for Alzheimer’s disease. ACI-24.060 is an anti-Abeta active immunotherapy candidate designed to induce an antibody response against the toxic forms of Abeta believed to drive plaque formation and Alzheimer’s disease progression.  By inducing plaque clearance and efficiently inhibiting plaque formation in the brain, ...